Approved in May 2018, Andexxa is the first and only available agent indicated for the reversal of the direct oral anticoagulants (DOACs). Previously, many health systems relied on the off-label use of the much less costly 4F-PCC.
Given its high cost, should hospital pharmacies add Andexxa to formulary for the reversal of DOACs during emergent bleeding?
Watch this video for the Lumere team’s analysis of the evidence.
This Content is provided “AS IS”, with all faults and without any warranty of any kind; any and all warranties are expressly disclaimed. No information in this Content is, or should be construed as medical advice, a guarantee of any product safety or any endorsement of any product or service; use of this Content is at your own risk. Lumere shall not be liable, in any way, for any use of this Article or decisions made and/or actions taken based upon the contents herein. Discussion of experimental uses of drugs or medical product as described in this Content is for informational purposes only, and is not to be interpreted as an endorsement or encouragement of off-label use of any product.